Amprologix Advances First-in-Class Antibiotic Epidermicin NI01 Toward Human Trials
Key Insights
Amprologix (search) is completing preclinical safety studies for Epidermicin NI01 (search), a first-in-class antibiotic designed to treat resistant skin and other bacterial infections (search).
The novel antibiotic works through a different mechanism than existing treatments, enabling it to kill bacteria that have developed resistance to current antibiotics.
The company is initiating Series A funding to support first-in-human trials planned for next year and expand its pipeline using AI-driven drug discovery technology.
Amprologix (search), a portfolio company of Frontier IP Group PLC (search), is advancing its lead antibiotic candidate Epidermicin NI01 (search) through final preclinical studies as the company prepares for human clinical trials. The novel compound represents a first-in-class antibiotic designed to combat resistant bacterial infections (search), addressing a critical global health need identified by the World Health Organization.
Scientific Officer Mathew Upton explained that recent funding will support completion of preclinical safety assessments for Epidermicin NI01 (search). "This money is going to be used to advance our lead technology," Upton said. "We need to run some final assays to prove that the lead molecule Epidermicin is not toxic before we go into human trials."
Novel Mechanism Targets Resistant Pathogens
Epidermicin NI01 (search) distinguishes itself through a unique mechanism of action that differs from existing antibiotic treatments. This first-in-class approach enables the compound to kill bacteria that have developed resistance to current antibiotics, including those commonly encountered in clinical settings.
"It works in different ways to the current antibiotics that you might take for any bacterial or other infection," Upton explained. "The way it works means that the bacteria that we currently see in the clinic, which are resistant to current antibiotics, can be killed with our antibiotic."
The development comes amid growing concerns about antimicrobial resistance (search). The WHO's most recent report this year concluded that there are insufficient antimicrobials in development to meet future needs, particularly emphasizing the requirement for molecules of new classes that work through different mechanisms.
Clinical Development Timeline
Following completion of preclinical studies, Amprologix (search) plans to advance Epidermicin NI01 (search) into first-in-human trials for skin infections (search). The company has already initiated regulatory discussions necessary for clinical trial approval and is pursuing Series A funding to support this transition.
"What's next is to complete this preclinical work and then complete the paperwork required to advance into human clinical trials," Upton noted. The planned human clinical trials are scheduled for next year, focusing initially on skin infection applications.
AI-Driven Pipeline Expansion
Beyond its lead compound, Amprologix (search) is leveraging artificial intelligence to expand its antibiotic portfolio. The company employs an AI-driven accelerated evolution engine to generate molecules similar to Epidermicin NI01 (search) but with different mechanisms of action and clinical applications.
This approach has already yielded promising results, including a compound with activity against Clostridioides difficile (search), a priority pathogen identified by the WHO. "We have a whole compound that has activity against Clostridioides difficile (C. diff), the superbug people may have heard about," Upton said.
The Series A funding round will support both the clinical development of Epidermicin NI01 (search) and the expansion of this AI-generated pipeline. The company aims to develop multiple drug candidates targeting WHO-prioritized pathogens for future research and drug development.
Addressing Global Antimicrobial Shortage
The development of Epidermicin NI01 (search) addresses a critical gap in the antimicrobial pipeline. The WHO regularly monitors antibiotics in clinical and preclinical development, consistently identifying shortages of effective treatments for resistant infections.
Amprologix (search)'s approach of developing first-in-class antibiotics with novel mechanisms represents a strategic response to this challenge. By targeting resistant organisms through different pathways, the company's pipeline could provide new therapeutic options for infections that have become increasingly difficult to treat with existing antibiotics.